Italian tennis star Jannik Sinner enters Wimbledon as the defending champion and the leading contender for his fifth Grand Slam title.
In 2024, Sinner recorded two positive tests for clostebol, a prohibited steroid, which ultimately resulted in a suspension from February 9 to May 4 2025 after a settlement with the World Anti‑Doping Agency.
Authorities accepted Sinner’s claim that the substance entered his system through a physiotherapist’s spray used to treat a finger cut, concluding that he did not intend to cheat but was accountable for his team’s negligence.
The case sparked controversy, with many players questioning whether Sinner received preferential treatment because of his high profile and access to top legal counsel.
The positive results stemmed from separate tests conducted in March 2024 and were reviewed by an independent tribunal in August 2024.
Despite the findings, Sinner continued competing until his suspension, capturing his third major title at the Australian Open in January 2025, the last tournament he played before the ban.
He resumed competition at the Italian Open in May 2025 and subsequently reached the French Open final, finishing runner‑up to Carlos Alcaraz.
The tribunal ruled that Sinner bore no fault or negligence, imposing no period of ineligibility but ordering the forfeiture of prize money and ranking points earned at the March 2024 Indian Wells event.
World Anti‑Doping Agency appealed the decision, leading to a three‑month suspension that nonetheless allowed Sinner to return in time for the 2025 French Open, a timing that drew further criticism.
Former British No. 1 Tim Henman described the outcome as “convenient” and warned that settlements and negotiations undermine the binary nature of anti‑doping enforcement, leaving a sour taste for players and fans alike.
Sinner now focuses on defending his Wimbledon crown, while the broader tennis community continues to scrutinize the handling of his anti‑doping case.
